A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 Administered Either as a Monotherapy or in Combination With Pembrolizumab in Patients With Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies
Latest Information Update: 15 May 2025
At a glance
- Drugs CTX-471 (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Head and neck cancer; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man
- Sponsors Compass Therapeutics
Most Recent Events
- 08 May 2025 According to a Compass Therapeutics media release, data demonstrating durable clinical responses in Phase 1 presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.
- 13 Feb 2025 Planned primary completion date changed from 1 Feb 2025 to 1 Apr 2025.
- 08 Nov 2024 According to a Compass Therapeutics media release, company presented its poster presentation entitled Pharmacodynamic and Response Biomarkers in the Monotherapy Arm of a Phase 1 Trial of CTX-471, a Novel Anti-CD137 Agonist Antibody at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting, from November 6-10, 2024 in Houston, TX.